Table 4.
Clinical Outcomes at 2 Years According to Various Usage Pattern of Vasodilator
|
Overall (n=1895) |
No vasodilator (n=359) |
Vasodilator | P value* | |||
|---|---|---|---|---|---|---|
|
Nonnitrate vasodilator (n=1187) |
Conventional nitrate (n=209) |
Combination (n=140) |
||||
| Primary end point † | 89 (4.7) | 18 (5.0) | 44 (3.7) | 15 (7.2) | 12 (8.6) | 0.017 |
| Cardiac death | 4 (0.2) | 2 (0.6) | 2 (0.2) | 0 | 0 | 0.410 |
| Acute coronary syndrome ‡ | 58 (3.1) | 8 (2.2) | 25 (2.1) | 13 (6.2) | 12 (8.6) | <0.001 |
| Non–ST‐segment–elevation myocardial infarction | 4 (0.2) | 0 | 1 (0.1) | 1 (0.5) | 2 (1.4) | 0.007 |
| Unstable angina | 54 (2.8) | 8 (2.2) | 24 (2.0) | 12 (5.7) | 10 (7.1) | <0.001 |
| Arrhythmia | 31 (1.6) | 9 (2.5) | 20 (1.7) | 2 (1.0) | 0 | 0.200 |
| Atrial fibrillation | 10 (0.5) | 3 (0.8) | 7 (0.6) | 0 | 0 | 0.460 |
| Atrioventricular block | 7 (0.4) | 4 (1.1) | 2 (0.2) | 1 (0.5) | 0 | 0.063 |
| ventricular tachycardia or ventricular fibrillation | 7 (0.4) | 0 | 6 (0.5) | 1 (0.5) | 0 | 0.473 |
| Cardiac arrest | 3 (0.2) | 1 (0.3) | 2 (0.2) | 0 | 0 | 0.828 |
| All‐cause death | 13 (0.7) | 6 (1.7) | 5 (0.4) | 0 | 2 (1.4) | 0.030 |
| Rehospitalization | 295 (15.6) | 53 (14.8) | 187 (15.8) | 29 (13.9) | 26 (18.6) | 0.654 |
| Medication change § | 1172 (62.7) | 203 (60.8) | 747 (62.9) | 132 (63.2) | 90 (64.7) | 0.844 |
Values are expressed as n (%).
*
The P values are derived from the chi‐square test for group comparison.
†
The primary end point was a composite of cardiac death, acute coronary syndrome, and new‐onset arrhythmia.
‡
There was no ST‐segment–elevation myocardial infarction in all groups.
§
Data for medication change were available in 334 (93.0%) with no vasodilator group, 1187 (100%) with nonnitrate vasodilator group, 209 (100%) with conventional nitrate group, and 139 (99.3%) with combination group.